Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-22-3p antagomir
- Development stage
- Preclinical
- Lead developer
- AptamiR Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
miR-22-3p antagomir (Generation 2.5) is an antisense oligonucleotide therapeutic being developed by AptamiR Therapeutics for the treatment of cardiometabolic disorders, including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), and type 2 diabetes. The drug acts as an antagomir, a type of chemically engineered oligonucleotide that specifically binds to and inhibits microRNA-22-3p (miR-22-3p). By antagonizing miR-22-3p, the therapy aims to modulate metabolic pathways, potentially increasing energy expenditure and improving insulin sensitivity. The program is currently in the IND-enabling phase, utilizing optimized oligonucleotide chemistry to enhance stability and metabolic targeting.
- Other names
- miR-22-3p AntagomirsmiR22-3p AntagomirsmiR 22-3p AntagomirsmiR-22-3p Antagomir Generation 2.5miR22-3p Antagomir Generation 2.5miR 22-3p Antagomir Generation 2.5miR-22-3p antagomir (Gen 2.5)miRNASH
02
Targets
miR-22-3p (MicroRNA 22-3p)
Beyond the preview
Go deeper on miR-22-3p antagomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-22-3p antagomir.